Backed by Norwest.
About the role
The Senior Manager, New Product Planning translates clinical, scientific, and market insight into commercial strategy for Avalyn's pipeline. This role will help drive core New Product Planning workstreams, including target Product Profile development, market landscape and epidemiology assessment, market research, forecasting, and early commercialization planning. This role will serve as a key commercial voice in partnership with our cross-functional program teams.
What they're looking for
- A minimum of a Bachelor's degree required, Advanced degree (e.g. MS, PhD, PharmD or equivalent) preferred
- 5–8 plus years of experience in biotech/pharmaceutical new product planning, marketing, commercial analytics, commercial strategy, life sciences strategy consulting or related experience is required
- Rare disease, respiratory/pulmonary, or specialty pharmaceutical experience strongly preferred
- Experience in a growing or small-company commercial organization is a plus
- Strong cross-functional collaboration and influence skills
- Ability to collaborate effectively and influence without formal authority across Clinical, Regulatory, Medical Affairs, Finance, and other cross-functional teams
More about this role
Avalyn aims to transform the treatment paradigm for pulmonary fibrosis and other serious, rare respiratory diseases. The company is advancing optimized inhaled formulations of established antifibrotic medicines designed to deliver drug directly to the lungs, enhance local efficacy, and reduce systemic side effects. Avalyn’s AP01 program is an optimized inhaled formulation of pirfenidone currently being evaluated in MIST, a global Phase 2b clinical trial in patients with progressive pulmonary fibrosis (PPF). AP01 has demonstrated encouraging safety and clinical activity across Phase 1b and an ongoing, multi-year open-label extension trial, with long-term data supporting the potential to preserve lung function while improving tolerability relative to historical oral pirfenidone. Avalyn’s AP02 program is an optimized inhaled formulation of nintedanib currently being evaluated in AURA-IPF, a global Phase 2 clinical trial in patients with idiopathic pulmonary fibrosis (IPF). Avalyn is also advancing AP03, an inhaled fixed-dose combination of pirfenidone and nintedanib, designed to deliver multiple antifibrotic mechanisms through a single lung-targeted platform. By leveraging its...
Browse similar: Startup jobs · Boston